Follicular helper T (TFH) cells specific to SARS-COV-2 virus
AssigneeThe University of Osaka
InventorsSho Yamasaki, Xiuyuan Lu, Yuki Hosono, Shigenari Ishizuka, Kazuo Yamashita, Nicolas Claude Paul Sax
Life of this patent
Estimating the term…
Abstract
Follicular helper T cells specific to SARS-CoV-2 virus are provided. The present disclosure is based on the finding of public TfhTCR specific to spike (S) protein common to various patients, and has identified for the first time a public TCR specific to the SARS-CoV-2 virus and its MHC and antigenic epitopes to promote efficient immune responses, particularly those of B cells that produce neutralizing antibodies. For example, the present disclosure provides a composition containing an epitope specific to SARS-CoV-2 virus for inducing a follicular T cell.
Claims19
A method for inducing a follicular T cell reactive with SARS-CoV-2, comprising a step of administering SARS-CoV-2 protein or a part thereof to a test subject, wherein said follicular T cell has a TCRαβ pair selected from the group consisting of SEQ ID NO:
- 2 and SEQ ID NO:
- 3, SEQ ID NO:
- 2 and SEQ ID NO:
- 4, SEQ ID NO:
- 14 and SEQ ID NO:
- 15, SEQ ID NO:
- 16 and SEQ ID NO:
- 15, SEQ ID NO:
- 17 and SEQ ID NO:
- 18, SEQ ID NO:
- 19 and SEQ ID NO:
- 20, SEQ ID NO:
- 21 and SEQ ID NO:
- 20, SEQ ID NO:
- 22 and SEQ ID NO:
- 23, SEQ ID NO:
- 2 and SEQ ID NO:
- 24, SEO ID NO:
- 25 and SEQ ID NO:
- 26, SEQ ID NO:
- 27 and SEQ ID NO:
- 28, SEQ ID NO:
- 29 and SEQ ID NO:
- 28, SEQ ID NO:
- 30 and SEQ ID NO:
- 31, SEQ ID NO:
- 32 and SEQ ID NO:
- 33, SEQ ID NO:
- 34 and SEQ ID NO:
- 35, or SEQ ID NO:
- 36 and SEQ ID NO:
- 37.
A method for inducing a follicular T cell reactive with at least one coronavirus, comprising a step of administering a SARS-CoV-2 protein or a part thereof to a test subject, wherein said follicular T cell is a public follicular T cell.
A method for enhancing immunity acquisition against SARS-CoV-2, comprising:
- (a) obtaining a biological sample from a subject:
- (b) isolating, follicular T cells from said biological sample:
- (c) contacting said follicular T cells with a SARS-CoV-2 protein or a part thereof ex vivo;
- (d) expanding said follicular T cells reactive with SARS-CoV-2 ex vivo under conditions suitable for T cell proliferation;
- and (e) administering said expanded follicular T cells to the subject via intravenous injection.
Dependencies are inferred from the claim text.